Enhancing cytotoxic therapies for breast and prostate cancers with polyunsaturated fatty acids

Irshad A A Shaikh, Iain Brown, Klaus W J Wahle, Steven D Heys

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The role of omega-3 and omega-6 fatty acids has been extensively studied in most of the human malignancies including breast, colon, prostate, pancreas, and stomach cancers. In particular, the role of omega-3 and omega-6 fatty acids in carcinogenesis has been extensively investigated in epidemiological, laboratory cell culture studies and studies in vivo in animal. Findings from these studies suggest that omega-3 and omega-6 fatty acids are cytotoxic in different cancers and act synergistically with cytotoxic drugs. Although experimental evidence for the potential beneficial role of polyunsaturated fatty acids (PUFAs) in enhancing the effectiveness of various chemotherapeutic agents in animal models and in cell culture studies is increasing, there are only a few reports that have shown supportive evidence for linking these natural compounds with augmentation of anticancer chemotherapeutics in human trials. This review presents evidence for a commonality in the proposed molecular mechanisms of action elicited by various PUFAs believed to be responsible for their enhancement of the effectiveness of anticancer chemotherapy, specifically in breast and prostate cancers, and reviews laboratory and animal studies and few reported human clinical trials. It concludes that sufficient evidence is available to suggest that major clinical trials with these natural compounds as adjuncts to standard therapies should be undertaken as a priority.
Original languageEnglish
Pages (from-to)284-296
Number of pages13
JournalNutrition and Cancer
Volume62
Issue number3
Early online date31 Mar 2010
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Omega-6 Fatty Acids
Unsaturated Fatty Acids
Prostatic Neoplasms
Breast Neoplasms
Cell Culture Techniques
Clinical Trials
Laboratory Animals
Pancreatic Neoplasms
Colonic Neoplasms
Stomach Neoplasms
Neoplasms
Carcinogenesis
Therapeutics
Animal Models
Drug Therapy
Pharmaceutical Preparations

Cite this

Enhancing cytotoxic therapies for breast and prostate cancers with polyunsaturated fatty acids. / Shaikh, Irshad A A; Brown, Iain; Wahle, Klaus W J; Heys, Steven D.

In: Nutrition and Cancer, Vol. 62, No. 3, 04.2010, p. 284-296.

Research output: Contribution to journalArticle

Shaikh, Irshad A A ; Brown, Iain ; Wahle, Klaus W J ; Heys, Steven D. / Enhancing cytotoxic therapies for breast and prostate cancers with polyunsaturated fatty acids. In: Nutrition and Cancer. 2010 ; Vol. 62, No. 3. pp. 284-296.
@article{9c1205a4fbcb4de2afddbca0374e1c16,
title = "Enhancing cytotoxic therapies for breast and prostate cancers with polyunsaturated fatty acids",
abstract = "The role of omega-3 and omega-6 fatty acids has been extensively studied in most of the human malignancies including breast, colon, prostate, pancreas, and stomach cancers. In particular, the role of omega-3 and omega-6 fatty acids in carcinogenesis has been extensively investigated in epidemiological, laboratory cell culture studies and studies in vivo in animal. Findings from these studies suggest that omega-3 and omega-6 fatty acids are cytotoxic in different cancers and act synergistically with cytotoxic drugs. Although experimental evidence for the potential beneficial role of polyunsaturated fatty acids (PUFAs) in enhancing the effectiveness of various chemotherapeutic agents in animal models and in cell culture studies is increasing, there are only a few reports that have shown supportive evidence for linking these natural compounds with augmentation of anticancer chemotherapeutics in human trials. This review presents evidence for a commonality in the proposed molecular mechanisms of action elicited by various PUFAs believed to be responsible for their enhancement of the effectiveness of anticancer chemotherapy, specifically in breast and prostate cancers, and reviews laboratory and animal studies and few reported human clinical trials. It concludes that sufficient evidence is available to suggest that major clinical trials with these natural compounds as adjuncts to standard therapies should be undertaken as a priority.",
author = "Shaikh, {Irshad A A} and Iain Brown and Wahle, {Klaus W J} and Heys, {Steven D}",
year = "2010",
month = "4",
doi = "10.1080/01635580903407189",
language = "English",
volume = "62",
pages = "284--296",
journal = "Nutrition and Cancer",
issn = "0163-5581",
publisher = "Routledge",
number = "3",

}

TY - JOUR

T1 - Enhancing cytotoxic therapies for breast and prostate cancers with polyunsaturated fatty acids

AU - Shaikh, Irshad A A

AU - Brown, Iain

AU - Wahle, Klaus W J

AU - Heys, Steven D

PY - 2010/4

Y1 - 2010/4

N2 - The role of omega-3 and omega-6 fatty acids has been extensively studied in most of the human malignancies including breast, colon, prostate, pancreas, and stomach cancers. In particular, the role of omega-3 and omega-6 fatty acids in carcinogenesis has been extensively investigated in epidemiological, laboratory cell culture studies and studies in vivo in animal. Findings from these studies suggest that omega-3 and omega-6 fatty acids are cytotoxic in different cancers and act synergistically with cytotoxic drugs. Although experimental evidence for the potential beneficial role of polyunsaturated fatty acids (PUFAs) in enhancing the effectiveness of various chemotherapeutic agents in animal models and in cell culture studies is increasing, there are only a few reports that have shown supportive evidence for linking these natural compounds with augmentation of anticancer chemotherapeutics in human trials. This review presents evidence for a commonality in the proposed molecular mechanisms of action elicited by various PUFAs believed to be responsible for their enhancement of the effectiveness of anticancer chemotherapy, specifically in breast and prostate cancers, and reviews laboratory and animal studies and few reported human clinical trials. It concludes that sufficient evidence is available to suggest that major clinical trials with these natural compounds as adjuncts to standard therapies should be undertaken as a priority.

AB - The role of omega-3 and omega-6 fatty acids has been extensively studied in most of the human malignancies including breast, colon, prostate, pancreas, and stomach cancers. In particular, the role of omega-3 and omega-6 fatty acids in carcinogenesis has been extensively investigated in epidemiological, laboratory cell culture studies and studies in vivo in animal. Findings from these studies suggest that omega-3 and omega-6 fatty acids are cytotoxic in different cancers and act synergistically with cytotoxic drugs. Although experimental evidence for the potential beneficial role of polyunsaturated fatty acids (PUFAs) in enhancing the effectiveness of various chemotherapeutic agents in animal models and in cell culture studies is increasing, there are only a few reports that have shown supportive evidence for linking these natural compounds with augmentation of anticancer chemotherapeutics in human trials. This review presents evidence for a commonality in the proposed molecular mechanisms of action elicited by various PUFAs believed to be responsible for their enhancement of the effectiveness of anticancer chemotherapy, specifically in breast and prostate cancers, and reviews laboratory and animal studies and few reported human clinical trials. It concludes that sufficient evidence is available to suggest that major clinical trials with these natural compounds as adjuncts to standard therapies should be undertaken as a priority.

U2 - 10.1080/01635580903407189

DO - 10.1080/01635580903407189

M3 - Article

VL - 62

SP - 284

EP - 296

JO - Nutrition and Cancer

JF - Nutrition and Cancer

SN - 0163-5581

IS - 3

ER -